

| | | | | | |
|---|--|---|----|--------------------------|------------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | | Complete if Known | |
| Sheet | | 1 | of | 2 | Attorney Docket Number |
| | | | | USF.208TCXC1 | |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|---|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number - Kind Code ² (if known) | | | |
| | U1 | US-7,595,303 | 09-29-2009 | Mohapatra <i>et al.</i> | All |
| | U2 | US-7,655,772 | 02-02-2010 | Mohapatra | All |
| | U3 | | | | |
| | U4 | | | | |
| | U5 | | | | |
| | U6 | | | | |
| | U7 | | | | |
| | U8 | | | | |
| | U9 | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | |
|--------------------------|-----------------------|---|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | |
| | F1 | | | | |
| | F2 | | | | |
| | F3 | | | | |
| | F4 | | | | |
| | F5 | | | | |
| | F6 | | | | |

| | | |
|--------------------|--|-----------------|
| Examiner Signature | | Date Considered |
|--------------------|--|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**
 (use as many sheets as necessary)

Sheet 2 of 2

| <i>Complete if Known</i> | |
|--------------------------|---------------------|
| Application Number | 10/581,580 |
| Filing Date | March 29, 2007 |
| First Named Inventor | Shyam S. Mohapatra |
| Group Art Unit | 1635 |
| Examiner Name | Richard A. Schnizer |
| Attorney Docket Number | USF.208TCXC1 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|--|----------------|
| | R1 | CHHABRA, A. <i>et al.</i> "Silencing of Endogenous IL-10 in Human Dendritic Cells Leads to the Generation of an Improved CTL Response Against Human Melanoma Associated Antigenic Epitope, MART-1" <i>Clin Immunol.</i> , March 2008, 126(3):251-259. | |
| | R2 | HEALE, B.S.E. <i>et al.</i> "siRNA target site secondary structure predictions using local stable substructures" <i>Nucleic Acids Research</i> , 2005, 33(3):e30, pp. 1-10. | |
| | R3 | HILL, J.A. <i>et al.</i> "Immune Modulation by Silencing IL-12 Production in Dendritic Cells Using Small Interfering RNA" <i>The Journal of Immunology</i> , 2003, 171:691-696. | |
| | R4 | HU, W-Y. <i>et al.</i> "Inhibition of Retroviral Pathogenesis by RNA Interference" <i>Current Biology</i> , August 6, 2002, 12:1301-1311. | |
| | R5 | KRETSCHMER-KAZEMI, R. <i>et al.</i> "The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides" <i>Nucleic Acids Research</i> , 2003, 31(15):4417-4424. | |
| | R6 | LI, M. <i>et al.</i> "Immune Modulation and Tolerance Induction by RelB-Silenced Dendritic Cells through RNA Interference" <i>The Journal of Immunology</i> , 2007, 178:5480-5487. | |
| | R7 | NAIR, M.P.N. <i>et al.</i> "RNAi-directed Inhibition of DC-SIGN by Dendritic Cells: Prospects for HIV-1 Therapy" <i>The AAPS Journal</i> , 2005, 7(3):E572-E578. | |
| | R8 | NAWTAISONG, P. <i>et al.</i> "Effective suppression of Dengue fever virus in mosquito cell cultures using retroviral transduction of hammerhead ribozymes targeting the viral genome" <i>Virology Journal</i> , 2009, 6:73, pp. 1-17. | |
| | R9 | QIAN, H. <i>et al.</i> "Silencing CD40 in Dendritic Cells by siRNA" <i>12th International Congress of Immunology and 4th Annual Conference of FOCIS, Montreal, Canada, July 18-23, 2004</i> , 2004, pp. 339-348. | |
| | R10 | SHAO, Y. <i>et al.</i> "Effect of target secondary structure on RNAi efficiency" <i>RNA</i> , 2007, 13:1631-1640. | |
| | R11 | WESTERHOUT, E.M. <i>et al.</i> "A systematic analysis of the effect of target RNA structure on RNA interference" <i>Nucleic Acids Research</i> , 2007, 35(13):4322-4330. | |
| | R12 | YOSHINARI, K. <i>et al.</i> "Effects on RNAi of the tight structure, sequence and position of the targeted region" <i>Nucleic Acids Research</i> , 2004, 32(2):691-699. | |
| | R13 | | |

| Examiner Signature | Date Considered |
|--------------------|-----------------|
| | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.